DNLI — Denali Therapeutics Inc

Ownership history in Siren, L.L.C. · 6 quarters on record

This page tracks every 13F SEC filing in which Siren, L.L.C. reported a position in Denali Therapeutics Inc (DNLI). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position

1.21% (2024 Q3)

Avg. % of fund

0.73%

First filed

2024 Q3

Last filed

2025 Q4

Quarters held

6

Quarter	Action	Shares	Change	Chg %	% of Fund	Mkt Value	Price (EOQ)
2025 Q4	ADDED	1,396,513	+575,000	+70.0%	0.69%	$23.1M	$16.51
2025 Q3	UNCHANGED	821,513	—	0%	0.47%	$11.9M	$14.52
2025 Q2	UNCHANGED	821,513	—	0%	0.59%	$11.5M	$13.99
2025 Q1	REDUCED	821,513	-12,515	-1.5%	0.64%	$11.2M	$13.60

% of Fund (quarterly) DNLI price (monthly, adj. close)

Other funds also holding DNLI

As of 2025 Q4 — sorted by position size

Crestline Management, LP 3Y 7Y 87.02% Lynx1 Capital Management LP 3Y 5.81% Casdin Capital, LLC 3Y 7Y 1.89% Palo Alto Investors LP 3Y 7Y 1.47% DAFNA Capital Management LLC 3Y 7Y 1.22% STEMPOINT CAPITAL LP 1.19% Monashee Investment Management LLC 3Y 7Y 0.85% MASTERS CAPITAL MANAGEMENT LLC 3Y 7Y 0.67% PSP Research LLC 0.46% 1492 Capital Management LLC 3Y 7Y 0.43%

← Back to Siren, L.L.C. Holdings